ESMO Video Commentary - A new promise for a rare skin cancer

Speaker: Celeste Lebbe

A small phase II, single arm study presented at the European Cancer Congress (ECC 2015) in Vienna enrolled 24 patients with advanced and unresectable Merkel cell carcinoma. Only ten of the patients who were treated with pembrolizumab were available for response. Despite of the some of these patients have been treated only for few weeks and a follow-up is needed, experts are optimistic of these preliminary results, as Celeste Lebbe of Hôpital St. Louis in Paris, France, commented. Read more...

Discussion Points